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Research Highlights 
 In a population-based cohort of 235 patients diagnosed with oropharyngeal cancer, 60% of 
patients were positive for HRHPV.  
 After adjustment, patients with HPV positive OPC had 89% reduction in risk of death (HR = 
0.11, 95% CI 0.05-0.25), and an 85% reduction in risk of disease progression (HR = 0.15 95% CI 
0.07-0.30).  
 The prevalence of HPV 16 in OPC indicates the potentially significant impact of prophylactic 
immunisation on this increasingly incident disease. 
 
Abstract 
Oropharyngeal cancer (OPC) is increasing on a global scale, including the component driven by 
high-risk human papillomavirus (HR-HPV); contemporary data that provide insight into the 
prognosis of this disease in addition to the fraction attributable to HR-HPV are essential to inform 
primary and secondary disease management strategies. A population-based cohort of 235 patients 
diagnosed with OPC between 2013-15 in Scotland was assessed for HPV status using molecular 
genotyping. Associations between HR-HPV status and key clinical and demographic variables were 
estimated using the Pearson chi-squared test. Rates of overall survival (OS) and progression-free 
survival (PFS) were estimated and visualized using Kaplan–Meier curves. HPV DNA (largely HPV 16) 
was identified in 60% of cases. After adjustment for age, gender, deprivation, smoking, alcohol 
consumption and tumour stage, patients with HR-HPV positive OPC had 89% reduction in risk of death 
(HR = 0.11, 95% CI 0.05-0.25), and an 85% reduction in risk of disease progression (HR = 0.15 95% CI 
0.07-0.30). HPV positivity was not associated with age, deprivation or smoking status, whereas those 
who reported excess alcohol consumption were less likely to be HPV positive. The prevalence of HPV-
associated OPC is high in Scotland and strongly associated with dramatically improved clinical 
outcomes including survival. Demographic/behavioural variables did not reliably predict HPV 
positivity in this cohort which underlines the importance of laboratory confirmation. Finally, the 
dominance of HPV 16 in OPC indicates the significant impact of prophylactic immunisation on this 
disease.   
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Introduction 
Oropharyngeal cancer (OPC) is increasing globally and the rate has doubled in the past 15 years in the 
United Kingdom with clinicians describing it as an ‘epidemic’ [1-3]. In Scotland, OPC is one of the most 
increasingly incident cancers – especially among men [4]. Tobacco use and alcohol consumption 
remain the major risk factors for head and neck cancers however, an increase in high-risk human 
papillomavirus (HR-HPV) driven OPC has also been observed [5,6].  Analyses of Scottish Cancer 
Registry head and neck cancer incidence trends over the past 40 years show that the rate of laryngeal 
cancer, which is strongly associated with tobacco consumption, has remained essentially stable. Oral 
cancer, which is associated with alcohol consumption, is steadily increasing, while OPC has risen 
comparatively more rapidly with a rate that has increased nearly 3-fold in recent years and is projected 
to rise further[7]. In relation to risk factors in head and neck cancer in Scotland these trends indicate 
a continued role of tobacco, an increasing role of alcohol, and a dramatic and relatively new role of 
the HPV [8].  
 
The fraction of OPC associated with HPV varies significantly with geographic location; in the US 
prevalence is around 60% whereas in South America the attributable fraction is less than 5% [9].  A 
study of approximately 1500 archived OPC cases from 11 participating centres in the UK [10] 
(diagnosed between 2002 and 2011) showed approximately 50% were HR-HPV DNA-positive, largely 
for HPV type 16.  Furthermore, the main HPV genotype identified in oral rinse samples from the 
general Scottish population was HPV 16 [11]. HPV is thought to be acquired through sexual exposure 
[12,13] although the natural history of HPV-associated OPC is not as well defined as other HPV-
associated neoplasms such as cervix.    Although the increase in OPC incidence is of clear concern, 
patients with HPV-driven OPC generally have a better prognosis compared to those patients who are 
HPV-negative [14]. Of note, the International Collaboration on Oropharyngeal Cancer Network for 
Staging (ICON-S) has developed a new staging classification system informed by HPV-status which 
recognises the improved clinical outcomes; and this has now been incorporated into the 8th edition 
TNM classification [14]. 
Studies of North American populations suggest that the sociodemographic status of head and neck 
cancer patients may also be changing, with an increasing proportion of patients with OPC diagnosis 
being younger and more socioeconomically affluent [15]. This phenomenon is not mirrored in 
Scotland, since recent national cancer registry data show that patients from the most deprived areas 
consistently had the highest rates of OPC [8]. While the HPV status of OPCs is not available in Scottish 
cancer registry data, the association between deprivation and cancer rates may reflect the 
overwhelming influence of tobacco and alcohol consumption in head and neck cancer oncogenesis in 
Scotland. The Scottish population has historically had a high rate of smoking, with 45% of adults 
reporting as current or ex-regular cigarette smokers (as of 2016), with about 60% residing in the most 
deprived areas [16]. Excessive alcohol consumption in Scotland is also high with one in four adults 
consuming harmful levels in 2016 [16].  
 
Prior to 2013, HPV testing of OPC in Scotland was performed opportunistically at the treating 
clinician’s request, thereafter it was offered as a service to all Scottish health boards via the National 
reference laboratory facility. This evaluation is one of the first to assess outcomes in a prospective, 
population based cohort of OPC patients, where HPV genotyping has been performed by a 
standardised methodology in a centralised location. We present data on the prevalence of HPV in OPC 
in Scotland and the association with key social variables and clinical indicators/outcomes. 
Furthermore, we investigate whether improved outcome associated with HPV-driven OPC is reflected 
in populations where rates of tobacco use and alcohol are particularly high, such as the West of 
Scotland.   
 
Materials and Methods 
Dimension and characteristics of patient cohort  
All OPCs, including sub-sites of the tonsil, base of tongue, soft palate, and pharyngeal walls diagnosed 
in the West of Scotland Cancer Network between April 2013 and June 2015 underwent pathology 
review and prospective HPV genotyping as part of routine clinical care. The Health Boards included in 
the present analysis covered the following locations: West Dunbartonshire; East Dunbartonshire; East 
Renfrewshire; Glasgow City; Inverclyde, Renfrewshire, Forth Valley, Lanarkshire, Ayrshire and Arran 
which cover a population of approximately 2.5 million people.  All individuals accessing health care in 
Scotland are assigned a unique 10-digit number, which allows linkage of clinical, social and laboratory 
data.  Sociodemographic and clinical data were extracted from the West of Scotland Cancer Network 
Head and Neck Cancer Quality Performance Indicators, which are collected by all health boards in 
Scotland and used to drive quality improvement in cancer care across NHS Scotland and clinical 
records.  The variables collected were: Date of diagnosis - taken as date of initial diagnostic biopsy 
sample collection, age at diagnosis, cancer stage; 7th edition TNM classification (TNM),  8th edition TNM 
classification for HPV positive OPCs/International Collaboration on Oropharyngeal Cancer Network for 
Staging (ICON-S) [14] which takes into account HPV status, treatment modality,  date of relapse if 
occurred  and if applicable date and cause of death, smoking status (never v. ever) at time of diagnosis 
and self-reported alcohol excess. Alcohol excess is defined by NHS Scotland as consuming alcohol at 
>=21 units or more per week for men and >=14 units per week for women] or documentation of 
“heavy”, “excessive” or “dependency” on alcohol within clinical records). In addition, area-based 
socioeconomic status was obtained - via the Scottish Index of Multiple Deprivation (SIMD) where 1 
and 5 are the most and least deprived respectively.    Data were extracted by treating clinicians and 
all patient identifiable data were removed prior to statistical analysis. Study governance and ethical 
considerations were through NHS Greater Glasgow and Clyde Research and Development Office, the 
Clinical Effectiveness Team and a data sharing agreement with the West of Scotland Cancer Network, 
NHS. Data was censored at November 2016   
 
Nucleic acid extraction & HPV genotyping 
 
Formalin fixed, paraffin-embedded (FFPE) block was selected and a 10 μm section obtained for nucleic 
acid extraction. Nucleic acid extraction was performed using reagents within the DNA mini kit (Qiagen, 
Hilde Germany) with an adaptation to the protocol to maximise recovery of HPV DNA [17].  
Subsequently, HPV genotyping was performed using the PCR and luminex based Optiplex HPV 
Genotyping test (Diamex, Heidelberg, Germany). This assay detects 24 HPV types including all 
established HR types and, as a check for specimen adequacy, incorporates a cellular housekeeping 
control (betaglobin). This assay was used for the recent UK prevalence study of 1500 OPC referred to 
earlier [10] Agreement of the this assay with p16INK4a immunohistochemistry has been shown to be 
90% in oropharyngeal samples with no significant difference in the distribution of discordant results 
between the two tests. Furthermore, positivity according to this assay has been shown to correlate 
with cause-specific survival in Scottish cohorts as reported in Wells et al (2015) [10, 18]. All testing was 
performed at a centralised reference laboratory.  
 
Analysis of HPV status with clinical outcomes 
Associations between HR-HPV status and clinical and demographic variables were estimated using the 
Pearson chi-squared test. Both unadjusted and adjusted odds ratios (ORs) for HPV positivity and 95% 
confidence intervals (CIs) were calculated using logistic regression. Linear trend test was performed 
to investigate whether there was an increasing trend in the risk of HPV positive OPC with increasing 
age. Rates of overall survival (OS) and progression-free survival (PFS) were determined and univariate 
comparisons visualized using Kaplan–Meier curves.  The univariate impact of each variable on survival 
was measured using Cox proportional-hazards regression. An adjusted model was created to obtain 
the adjusted hazard ratios for HR-HPV status with adjustment of the following covariates: gender, age 
at diagnosis (<50, 50-59, 60-69, 70-79 and 80+), SIMD, smoking and alcohol status and TNM 
classification 7 of cancer. Subset analysis on the HPV+ patients were carried out to obtain univariate 
and adjusted hazard ratio for ICON stage. 
All statistical analysis was carried out using R version 3.2.3. All variables with P-values <0.05 were 
considered to be statistically significant. 
Results 
Description of cohort 
A total of 235 patients were diagnosed with OPC between April 2013 and June 2015. Technically valid 
HPV results were obtained for 229 patients with 6 excluded due to non- amplification of the cellular 
housekeeping gene. Only 22 % of the 229 OPC patients were female and the median age was 60 (IQR 
54-69). Most of the cohort was resident in a deprived area (37.6% in SIMD1 and 21% in SIMD2). The 
majority reported having ever smoked tobacco (65%) with 31% reporting drinking alcohol to excess 
(Table 1).   
HPV positivity and association with extrinsic risk factors 
HPV DNA was identified in 60% of the cases (136/229). Single infections with 16, 18, 33, 35 were 
identified in 127, 2, 1, and 1 case, respectively. The occurrence of multiple infections of 16/6, 16/59, 
18/82, 6/16/33 and 18/59/82 all occurred in a single case each. All bar one of the HPV positive cases 
included at least 1 established HR-HPV type. 
 
Influence of gender and risk factors are summarised in Table 1. Men were twice as likely as women to 
have an HPV positive tumour (OR 2.44, 95% CI 1.18-5.05, P=0.02). Those who reported drinking alcohol 
to excess were 70% less likely to be HPV positive (OR 0.30, 95% CI 0.14-0.63, P=0.001). HPV positivity 
was not associated with social deprivation as measured by SIMD (P = 0.2) or age (linear trend P = 0.7), 
or smoking status (P = 0.1). 
HPV status and survival  
A total of 35 patients were excluded from the survival analysis: one was lost to follow-up and 34 
received treatment intent of best support palliative care due to frailty and were unable to tolerate 
treatment. Post-exclusions, the median follow-up time of the remaining cohort after OPC diagnosis 
was 2.2 years (range from 19 days to 3.4 years). In total, 23% patients (45/194) died and 28% patients 
(55/194) had disease progression during the follow-up period.  One-year OS rate for HPV negative 
patients was 75.7% while for HPV positive patients OS was 95.2%. One-year PFS rate for HPV negative 
and HPV positive patients was 67.1% and 92.7%, respectively (Figures 1 and 2). One-year OS rates for 
the patients who smoked was 86.4% compared with 90.2% for the patients who reported never 
smoking. One-year OS rate for the patients who drank alcohol to excess was 80.4% compared with 
91.5% for those who did not.  In our data we observed an increase in the point estimates for death 
and disease free survival as TNM classification 7 increased from stage 1 to 4, but use of ICON stage for 
the HPV positive population was not discriminatory.  
 
Univariate analysis also showed that HPV negative status and alcohol consumption were significantly 
associated with increased risk of death (both P<0.001, Table 2). After adjustment for age, gender, 
SIMD, smoking and drinking status and tumour stage, patients with HR-HPV positive OPC had 89% 
reduction in risk of death (HR = 0.11, 95% CI 0.05-0.24, P<0.001, Table 2), and had 84% reduction in 
risk of disease progression (HR = 0.15, 95% CI 0.07-0.30, P<0.001, Table 3) compared with those with 
HPV negative OPC. The risk of death increased with age in the fully adjusted model. Patients who 
reported drinking alcohol to excess had 2.3 times the risk of death (HR OS = 2.33, 95% CI 1.06-5.18, 
P=0.04) compared with those who did not drink alcohol to excess.  
 
Discussion 
We have conducted a detailed population-based evaluation to examine the impact of demographic, 
behavioural, and viral factors associated with OPC in a context where both disease prevalence and 
non-viral risk factors (alcohol consumption and smoking) are high.  We have demonstrated that HR-
HPV prevalence among OPCs in the West of Scotland was 60% and that HR-HPV positivity was higher 
in males compared to females, and lower amongst those who reported drinking alcohol to excess. We 
also confirmed that in our population HR-HPV status was strongly associated with improved overall 
and progression-free survival. It was of interest that individuals reporting tobacco exposure were as 
likely to have cancers associated with HR-HPV as those individuals who reported no history of tobacco 
use - a finding at variance with other previously reported UK data [19]. 
Studies suggest that incidence of HR-HPV detection in OPCs varies widely depending on geographic 
location and period of time.  We report HR-HPV rates of 49% among women and 62.4% among men, 
with an overall positivity of 60%. This is broadly in line with the UK based results of Schache et al [3] 
and reflects a more recent period of assessment.  Beyond the UK, studies of HR-HPV prevalence in 
OPCs in the most recent decade reports range from 6.1% in Spain [20], 38% in the Netherlands [21] 
and 62% in Denmark [22]. US estimates are consistently higher at around 60-70% [9]. A confounder 
to cross-study comparison is the different methods by which HPV positive status is defined, which vary 
across studies and include nucleic acid amplification tests, immunohistochemistry with p16INK4a,  in-
situ hybridisation and combinations thereof.  In this work we used a sensitive PCR-based assay to 
confirm HPV status rather than p16INK4a; this assay has been shown to have a high level of agreement 
(90%) with p16INK4a immunohistochemistry, with no difference in the distribution of discordant 
results in OPC cases. Furthermore, HPV status determined by this assay has been shown to be 
independently associated with disease specific survival as indicated in previous studies, national audit 
and the data outlined in the present manuscript [10,18]. Thus, although testing with multiple 
markers/chemistries for HPV status provides further validation, we are confident that the assay is a 
robust and credible marker of HPV status. Additionally, the advantage of this approach is that it also 
provides information on type specific prevalence to allow the monitoring of epidemiological trends.   
 
Country-specific data on the attributable fraction of HPV-associated disease are important as they will 
inform the decisions surrounding the utility and cost effectiveness of HPV vaccination including gender 
neutral vaccination.  Certainly, significant impact of the vaccine on HR-HPV prevalence and disease 
outcomes including high grade cervical intraepithelial neoplasia (CIN2+) has already been observed in 
young women attending for screening in Scotland [23,24].  As reports suggest that HPV vaccination 
induces HPV antibodies in the oral cavity it is reasonable to assume that the vaccine will ultimately 
have an impact on OPC incidence [25,26].   This may be realised more rapidly in a gender neutral 
programme given that we and others have shown a significantly higher prevalence of OPCs  associated 
with HPV in men compared to women [9]. 
We report an inverse association between HPV positivity and excess alcohol consumption.  No other 
factor including social deprivation or cancer stage was associated with viral status.   This is an 
interesting and important observation as it indicates that in Scotland, patient-related demographic 
and clinical factors cannot be reliably used to predict the HPV status of patients OPCs. Furthermore, 
we did not observe an inverse relationship between HPV positivity and smoking status unlike other 
studies [9] and this may have been affected by the high smoking rates and the socio-economic status 
of our study population (Table 1).  
In our data TNM classification 7 was more predictive of outcome than the new staging system that 
takes into account HPV status, although numbers were small. The British Association of Head and Neck 
Oncologists (BAHNO) have raised concerns of the use of TNM 8 and have suggested TNM 7 continues 
to be recorded.  While the new staging system reflects improved understanding of cancer biology and 
clinical outcome of HPV-positive OPCs, further research is required to define if TNM 8 is generalisable 
to all populations and can be used to change treatment decisions.  
In the adjusted analysis HPV status was strongly associated with improvement in overall and 
progression free survival during a median of 2-years follow up. For individuals whose disease recurs, 
the median time to progression was similar for HPV positive and HPV negative OPCs, with most people 
experiencing disease progression in the first year after completion of therapy [27]. The improvement 
in survival associated with HPV positive disease is in accordance with other studies of OPC; D’Souza et 
al (2016) recently reported a 66% reduction in the hazard of death among HPV positive OPC compared 
to HPV negative cases [28] and in other HPV-associated cancers [29,30].  It has been hypothesised that 
improved prognosis in HPV positive cancers may be due to better response rates to treatment through 
increased sensitivity to radiation and host immune response to the tumour [31].  While treatment for 
HPV positive and negative OPCs remains the same in many settings, the results of de-intensifying 
treatment trials in HPV positive OPC will be informative for future evidence-based management 
strategies [32]. The reduction in survival with increasing age and heavy alcohol consumption has 
implications for the ability to deliver and tolerate curative treatment, which may impact survival. 
Cause of death was out with the scope of the present study but nutritional factors and co-morbidities 
in these patient groups should be further evaluated.  
Conclusion 
In this evaluation of OPC patients in whom the prevalence of traditional risk factors of drinking and 
smoking was high; 60% of tumours were HPV positive with positivity dominated by HPV type 16. While 
we confirmed that in our population HR-HPV status was strongly associated with improved overall and 
progression-free survival, HPV status could not be reliably predicted by demographic/clinical 
characteristics alone emphasising the need for laboratory confirmation. While primary prevention of 
most OPCs through vaccination is likely to exert a significant influence on the burden of this disease 
in time, in the shorter term, Scotland must address other interventions to promote healthy living in 
order to reduce excessive alcohol consumption and smoking. Such interventions if successfully 
implemented, would have far-reaching benefits beyond the reduction of OPC.  
 
 
Funding 
Cancer Research UK, Development fund.  
 
Acknowledgments 
We would like to thank Julie Macdonell and Ian Downie, Department of Pathology, The Queen 
Elizabeth University Hospital, NHS Greater Glasgow and Clyde, for assistance with data extraction 
and members of the Scottish HPV Reference Laboratory for practical support. 
 
References 
 
1. Hussein AA, Helder MN, de Visscher JG, Leemans CR, Braakhuis BJ, de Vet HCW, Forouzanfar T. 
Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older 
patients: a systematic review. Eur J Cancer 2017; 82: 115-127.  
 
2. Mehanna H, Franklin N, Compton N, Robinson M, Powell N, Biswas-Baldwin N, Paleri V, Hartley A8, 
Fresco L, Al-Booz H, Junor E, El-Hariry I, Roberts S, Harrington K, Ang KK, Dunn J, Woodman C. 
Geographic variation in human papillomavirus-related oropharyngeal cancer: data from 4 
multinational randomized trials. Head Neck 2016; 38: E1863-9.  
 
3. Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck squamous cell 
cancer: a tale of three cancers? Clin Otolaryngol 2018 May 16. doi: 10.1111/coa.13144 [Epub ahead 
of print]. 
 
4. Junor EJ, Kerr GR, Brewster DH. Oropharyngeal cancer. Fastest increasing cancer in Scotland, 
especially in men. BMJ 2010; 340: c2512 doi:10.1136/bmj.c2512.  
 
5. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide 
trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550-9.  
 
6. Winn DM, Lee YC, Hashibe M, Boffetta P; INHANCE consortium. The INHANCE consortium: toward 
a better understanding of the causes and mechanisms of head and neck cancer. Oral Dis 2015; 21: 
685-93.  
 
7. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Head-and-Neck/ [accessed 
30th May 2018] 
 
8. Purkayastha M, McMahon AD, Gibson J, Conway DI. Trends of oral cavity, oropharyngeal and 
laryngeal cancer incidence in Scotland (1975-2012) – a socioeconomic perspective. Oral Oncol 2016; 
61: 70-5.  
 
9. Anantharaman D, Abedi-Ardekani B, Beachler DC, Gheit T, Olshan AF, Wisniewski K, et al. 
Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. Int J 
Cancer 2017; 140: 1968-1975.  
 
10. Schache AG, Powell NG, Cuschieri KS, Robinson M, Leary S, Mehanna H, et al. HPV-Related 
Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. 
Cancer Res 2016; 76: 6598-606.  
 
11. Conway DI, Robertson C, Gray H, Young L, McDaid LM, Winter AJ, et al. Human Papilloma Virus 
(HPV) Oral Prevalence in Scotland (HOPSCOTCH): A Feasibility Study in Dental Settings. PLoS One 2016; 
11: e0165847. 
 
12. Anantharaman D, Muller DC, Lagiou P, Ahrens W, Holcátová I, Merletti F, et al. Combined effects 
of smoking and HPV16 in oropharyngeal cancer. Int J Epidemiol 2016; 45: 752-61.  
 
13. Schnelle C, Whiteman DC, Porceddu SV, Panizza BJ, Antonsson A. Past sexual behaviors and risks 
of oropharyngeal squamous cell carcinoma: a case-case comparison. Int J Cancer 2017; 140: 1027-34.  
 
14. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation 
of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on 
Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016; 
17: 440-51.  
 
15. Dahlstrom KR, Bell D, Hanby D, Li G, Wang LE, Wei Q,et al. Socioeconomic characteristics of 
patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and 
sexual behavior. Oral Oncol 2015; 51: 832-8.  
 
16. https://beta.gov.scot/publications/scottish-health-survey-2016-volume-1-main-report/ (Table 1.1 
and 2.3 accessed 9th September 2018). 
 
17. Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, 
paraffin-embedded tissues. J Mol Diagn 2011; 13: 377-81. 
 
18. Wells LA, Junor EJ, Conn B, Pattle S, Cuschieri K. Population-based p16 and HPV positivity rates in 
oropharyngeal cancer in Southeast Scotland. J Clin Pathol. 2015 Oct;68(10):849-52 
 
19. Evans M, Newcombe R, Fiander A, Powell J, Rolles M, Thavaraj S, et al.. Human Papillomavirus-
associated oropharyngeal cancer: an observational  study of diagnosis, prevalence and prognosis in a 
UK population. BMC Cancer 2013; 13: 220.  
 
20. Rodrigo JP, Heideman DA, García-Pedrero JM, Fresno MF, Brakenhoff RH, Díaz Molina JP,et al.. 
Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain 
(1990-2009). Int J Cancer 2014; 134: 487-92.  
 
21. Henneman R, Van Monsjou HS, Verhagen CV, Van Velthuysen ML, Ter Haar NT, Osse EM, et al. 
Incidence Changes of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma and Effects 
on Survival in the Netherlands Cancer Institute, 1980-2009. Anticancer Res 2015; 35: 4015-22.  
 
22. Carlander AF, Grønhøj Larsen C, Jensen DH, Garnæs E, Kiss K, Andersen L,et al. Continuing rise in 
oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 
2014. Eur J Cancer 2017; 70: 75-82.  
 
23. Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C,et al. Changes in the prevalence 
of human papillomavirus following a national bivalent human papillomavirus vaccination programme 
in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17: 1293-302.  
 
24. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al.. Reduction of low- and high-
grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J 
Cancer 2014; 111: 1824-30.  
 
25. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral 
human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in 
Costa Rica. PLoS One 2013; 8: e68329.  
 
26. Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, et al. Quadrivalent Human 
Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the 
Mid-Adult Male Vaccine Trial. J Infect Dis 2016; 214: 1276-83.  
 
27. Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, et al. Human 
papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin 
Oncol. 2014 Oct 20;32(30):3365-73 
 
28. D'Souza G, Anantharaman D, Gheit T, Abedi-Ardekani B, Beachler DC, Conway DI,et al. Effect of 
HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases 
across three continents. Oral Oncol 2016; 62: 20-7.  
 
29. Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, et al. HPV status and favourable 
outcome in vulvar squamous cancer.  Int J Cancer 2017; 140: 1134-1146.  
 
30. Cuschieri K, Brewster DH, Graham C, Nicoll S, Williams AR, Murray GI, et al. Influence of HPV type 
on prognosis in patients diagnosed with invasive cervical cancer. Int J Cancer 2014; 135: 2721-6.  
 
 
31. Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human 
papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. 
Lancet Oncol 2017; 18: 803-11.  
 
32. Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven oropharyngeal cancer: Where 
do we stand? Clin Transl Radiat Oncol. 2017; 8: 4-11.
Variable Level Number (N = 229)* HR-HPV pos (N= 136)  Unadjusted  Adjusted (full model)** 
    n % n % OR 95% CI lower 95% CI upper p values OR 95% CI lower 95% CI upper p values 
Sex Female 51 22.3 25 49.0 1       1       
  Male 178 77.7 111 62.4 1.72 0.92 3.23 0.09 2.44 1.18 5.05 0.02 
Age <50 27 11.8 20 74.1 1 
  
    
  
  
  50-59 86 37.6 58 67.4 0.73 0.27 1.92 0.5   
  
  
  60-69 60 26.2 30 50.0 0.35 0.13 0.95 0.04   
  
  
  70-79 49 21.4 25 51.0 0.36 0.13 1.02 0.05   
  
  
  80 and over 7 3.1 3 42.9 0.26 0.05 1.48 0.1   
  
  
  Age in years (19-91) 229   
 
  0.97 0.95 1 0.04 (trend) 0.99 0.97 1.02 0.7 (trend) 
SIMD 1: most deprived 86 37.6 44 51.2 1 
  
  1 
  
  
  2 48 21.0 27 56.3 1.23 0.6 2.5 0.6 1.01 0.44 2.33 1.0 
  3 35 15.3 26 74.3 2.76 1.16 6.57 0.02 4.24 1.45 12.35 0.01 
  4 29 12.7 20 69.0 2.12 0.87 5.18 0.1 1.75 0.64 4.75 0.3 
  5: least deprived 19 8.3 13 68.4 2.07 0.72 5.94 0.2 1.39 0.4 4.86 0.6 
  Missing 12 5.2 6 50.0   
  
  0.94 0.18 5 0.9 
Smoking status No  63 27.5 50 79.4 1 
  
  1 
  
  
  Yes 149 65.1 77 51.7 0.28 0.14 0.55 0.0003 0.52 0.23 1.17 0.1 
  Missing 17 7.4 9 52.9   
  
  1.12 0.18 6.94 0.9 
Alcohol status No  129 56.3 91 70.5 1 
  
  1 
  
  
  Yes 71 31.0 30 42.3 0.31 0.17 0.56 0.0001 0.3 0.14 0.63 0.001 
  Missing 29 12.7 15 51.7   
  
  0.45 0.12 1.69 0.2 
Smoking & 
Alcohol 
No/either 138 60.3 98 72.1 1        
 Both 66 28.8 27 19.8 0.28 0.15 0.52 0.00005     
 Missing 25 10.9 11 8.1         
TNM stage 1 13 5.7 2 15.4 1 
  
  1 
  
  
  2 26 11.4 11 42.3 4.03 0.74 21.98 0.1 10.94 1.6 74.91 0.01 
  3 20 8.7 13 65.0 10.21 1.75 59.65 0.01 23.37 3.09 176.86 0.002 
  4a 148 64.6 100 67.6 11.46 2.44 53.74 0.002 23.8 3.99 141.98 0.001 
  4b 12 5.2 6 50.0 5.5 0.84 36.2 0.08 17.65 1.94 160.87 0.01 
  4c 4 1.7 2 50.0 5.5 0.46 65.16 0.2 8.38 0.63 112.14 0.1 
  Missing 6 2.6 2 33.3   
  
  5.81 0.39 86.24 0.2 
 
*Valid HPV results available for 229/235 cases 
**An Adjusted for all variables in the table with the exception of treatment.  It is highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity. 
Table 1 Factors associated with high-risk human papillomavirus (HR-HPV) among OPC cases 
 
 
  
Variable Level Number 
(N = 
194)* 
Number 
with all 
cause 
death 
Person 
years 
follow 
up 
Rate 
per 100 
person 
years 
95% CI 
Lower  
95% 
CI 
Upper  
Univariate 
HR 
Lower 
95% CI 
Upper 
95% CI 
p value Adjusted 
(full) 
HR**  
Lower 
95% CI 
Upper 
95% CI 
p value 
HR-HPV status Negative 70 31 132.7 23.4 15.9 33.1 1.00       1.00       
  Positive 124 14 269.8 5.2 2.8 8.7 0.20 0.11 0.39 <0.00001 0.11 0.05 0.24 <0.00001 
Sex Female 39 7 80.8 8.7 3.5 17.9 1.00 
  
  1.00 
  
  
  Male 155 38 321.8 11.8 8.4 16.2 1.33 0.59 2.99 0.5 1.04 0.44 2.69 0.9 
Age <50 25 1 60.3 1.7 0.04 9.2 1.00 
  
  1.00 
  
  
  50-59 79 13 172.2 7.5 4.0 12.9 4.45 0.58 34.04 0.2 1.55 0.34 14.88 0.6 
  60-69 50 12 98.5 12.2 6.3 21.3 7.25 0.94 55.82 0.06 1.92 0.40 18.93 0.5 
  70-79 38 18 69.6 25.9 15.3 40.9 14.59 1.94 109.70 0.01 10.39 2.42 97.07 0.0007 
  80 and over 2 1 2.0 48.9 1.2 272.6 28.87 1.80 463.90 0.02 104.44 6.53 1744.56 0.003 
SIMD 1: most deprived 68 20 132.0 15.1 9.3 23.4 1.00 
  
  1.00 
  
  
  2 37 6 78.4 7.7 2.8 16.7 0.51 0.20 1.26 0.1 0.66 0.21 1.81 0.4 
  3 33 7 70.0 10.0 4.0 20.6 0.57 0.23 1.42 0.2 1.30 0.47 3.25 0.6 
  4 27 9 53.1 17.0 7.8 32.2 1.11 0.51 2.45 0.8 2.77 1.09 6.70 0.03 
  5: least deprived 18 3 38.6 7.8 1.6 22.7 0.51 0.15 1.73 0.3 0.91 0.23 2.70 0.9 
  Missing 11 0 30.4 0.0 0.0 12.1   
  
  0.11 0.00 1.18 0.07 
Smoking status No  61 10 129.0 7.8 3.7 14.3 1.00 
  
  1.00 
  
  
  Yes 118 34 235.7 14.4 10.0 20.2 2.06 0.99 4.30 0.05 1.64 0.64 4.45 0.3 
  Missing 15 1 37.9 2.6 0.1 14.7   
  
  4.23 0.28 48.34 0.3 
Alcohol status No  118 18 256.9 7.0 4.2 11.1 1.00 
  
  1.00 
  
  
  Yes 51 24 84.7 28.3 18.1 42.1 4.34 2.32 8.12 <0.00001 2.32 1.06 5.18 0.04 
  Missing 25 3 61.0 4.9 1.0 14.4   
  
  0.69 0.12 2.82 0.6 
TNM stage 1 13 2 27.6 7.2 0.9 26.2 1.00 
  
  1.00 
  
  
  2 23 10 41.2 24.3 11.6 44.7 3.20 0.70 14.64 0.1 3.20 0.86 17.30 0.08 
  3 20 2 45.5 4.4 0.5 15.9 0.60 0.09 4.29 0.6 3.85 0.53 28.22 0.2 
  4a-c*** 133 31 273.5 11.3 7.7 16.1 1.50 0.36 6.26 0.6 9.97 2.57 56.41 0.0005 
  Missing 5 0 14.8 0.0 0.0 24.9   
  
    
  
  
ICON 
stage***** 
1 16 3 34.3 8.7 1.8 25.6 1.00 
  
    
  
  
  2 71 4 156.8 2.6 0.7 6.5 0.30 0.07 1.34 0.1   
  
  
  3-4**** 36 7 75.7 9.2 3.7 19.0 0.97 0.24 3.87 1.0   
  
  
  Missing 1 0 3.0 0.0 0.0 122.9   
  
    
  
  
 
* individual removed from OS analysis as lost follow up (no date of death and no date of alive); individuals also removed from OS analysis as treatment = BSC 
**An Adjusted for all variables in the table with the exception of ICON stage.  They are highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity. 
***For TNM stage, 4a-c combines the levels 4a (126 cases, 30 died), 4b (6 cases, 1 died) and 4c (1 case, 0 died). 
****For ICON stage, 3-4 combines the levels 3 (35 cases, 7 died) and 4 (1 case, 0 died). 
*****Only select HRHPV+ cases N=124 
 
Table 2 Hazard ratios for OS 
 
 
 
 
  
Variable Level Number 
(N = 194) 
Number 
recur or 
die 
Person 
years 
follow 
up 
Rate 
per 100 
person 
years 
95% CI 
Lower  
95% CI 
Upper  
Univariate 
HR 
Lower 
95% CI 
Upper 
95% CI 
p value Adjusted 
(full) 
HR* 
Lower 
95% CI 
Upper 
95% CI 
p value 
HR-HPV status Negative 70 35 129.6 27.0 18.8 37.6 1.00       1.00       
  Positive 124 20 263.2 7.6 4.6 11.7 0.27 0.16 0.48 <0.00001 0.15 0.07 0.30 <0.00001 
Sex Female 39 9 79.8 11.3 5.2 21.4 1.00 
   
1.00 
  
  
  Male 155 46 313.0 14.7 10.8 19.6 1.30 0.64 2.66 0.5 0.98 0.47 2.24 1.0 
Age <50 25 2 60.1 3.3 0.4 12.0 1.00 
   
1.00 
  
  
  50-59 79 17 168.1 10.1 5.9 16.2 3.12 0.72 13.54 0.1 1.46 0.41 7.79 0.6 
  60-69 50 14 97.9 14.3 7.8 24.0 4.37 0.99 19.25 0.051 1.59 0.42 8.71 0.5 
  70-79 38 21 64.6 32.5 20.1 49.7 9.55 2.23 40.91 0.002 8.65 2.57 44.83 0.0002 
  80 and over 2 1 2.0 48.9 1.2 272.6 15.93 1.43 176.98 0.02 45.72 3.49 454.44 0.007 
SIMD 1: most deprived 68 23 129.0 17.8 11.3 26.8 1.00 
   
1.00 
  
  
  2 37 9 76.7 11.7 5.4 22.3 0.65 0.30 1.41 0.3 1.06 0.42 2.49 0.9 
  3 33 9 67.1 13.4 6.1 25.5 0.67 0.30 1.49 0.3 1.35 0.55 3.05 0.5 
  4 27 9 52.1 17.3 7.9 32.8 0.95 0.44 2.05 0.9 2.10 0.85 4.88 0.1 
  5: least deprived 18 5 37.5 13.3 4.3 31.1 0.76 0.29 2.00 0.6 1.34 0.45 3.39 0.6 
  Missing 11 0 30.4 0.0 0.0 12.1   
   
0.05 0.00 0.49 0.01 
Smoking status No  61 12 125.4 9.6 4.9 16.7 1.00 
   
1.00 
  
  
  Yes 118 41 231.3 17.7 12.7 24.0 2.00 1.03 3.90 0.04 1.70 0.73 4.12 0.2 
  Missing 15 2 36.0 5.5 0.7 20.0   
   
11.43 1.30 95.61 0.0003 
Alcohol status No  118 23 250.9 9.2 5.8 13.8 1.00 
   
1.00 
  
  
  Yes 51 27 82.3 32.8 21.6 47.7 3.84 2.17 6.79 <0.00001 2.08 0.99 4.33 0.1 
  Missing 25 5 59.5 8.4 2.7 19.6   
   
0.66 0.13 2.39 1.0 
TNM stage 1 13 2 27.1 7.4 0.9 26.7 1.00 
   
1.00 
  
  
  2 23 13 37.9 34.3 18.3 58.7 4.58 1.03 20.37 0.05 4.55 1.25 24.56 0.02 
  3 20 4 44.8 8.9 2.4 22.9 1.20 0.22 6.53 0.8 4.69 0.94 29.13 0.06 
  4a-c** 133 36 268.2 13.4 9.4 18.6 1.72 0.41 7.16 0.5 9.26 2.41 52.15 0.001 
  Missing 5 0 14.8 0.0 0.0 24.9   
   
0.61 0.00 12.65 0.8 
ICON stage**** 1 16 4 32.0 12.5 3.4 32.1 1.00 
   
  
  
  
  2 71 7 155.1 4.5 1.8 9.3 0.37 0.11 1.26 0.1   
  
  
  3-4*** 36 9 73.1 12.3 5.6 23.4 0.92 0.28 3.07 0.9   
  
  
  Missing 1 0 3.0 0.0 0.0 122.9   
   
  
  
  
 
*An Adjusted for all variables in the table with the exception of ICON stage.  They are highly associated with TNM stage therefore not included in the adjusted model to avoid collinearity. 
**For TNM stage, 4a-c combines the levels 4a (126 cases, 34 died/recur), 4b (6 cases, 2 died/recur) and 4c (1 case, 0 died/recur). 
***For ICON stage, 3-4 combines the levels 3 (35 cases, 9 died/recur) and 4 (1 case, 0 died/recur). 
*****Only select HRHPV+ cases N=124 
Table 3 Hazard ratios for PFS 
 
 
 
 
 
  
     OS  PFS 
Variable Level HR Lower 95% 
CI 
Upper 95% 
CI 
p value HR Lower 95% 
CI 
Upper 95% 
CI 
p value 
Sex Female 1.00 
  
  1.00 
  
  
  Male 0.55 0.11 3.36 0.48 0.53 0.14 2.34 0.378 
Age <50 1.00 
  
  1.00 
  
  
  50-59 3.66 0.29 529.78 0.36 4.95 0.52 667.62 0.196 
  60-69 8.56 0.58 1313.37 0.13 8.31 0.65 1199.88 0.113 
  70-79 18.45 1.62 2678.93 0.01 21.83 2.27 2974.37 0.004 
  80 and over 160.13 0.53 58517.87 0.07 53.83 0.23 12923.17 0.119 
SIMD 1: most deprived 1.00 
  
  1.00 
  
  
  2 1.99 0.16 17.15 0.55 3.65 0.66 21.41 0.135 
  3 3.86 0.89 20.02 0.07 4.57 1.23 20.60 0.023 
  4 3.99 0.77 22.28 0.10 3.97 0.77 21.01 0.096 
  5: least deprived 1.45 0.01 21.12 0.82 3.77 0.32 29.32 0.252 
Smoking status No  1.00 
  
  1.00 
  
  
  Yes 1.95 0.38 13.20 0.43 1.54 0.42 6.37 0.518 
Alcohol status No  1.00 
  
  1.00 
  
  
  Yes 5.30 1.28 28.40 0.02 5.19 1.49 20.62 0.009 
ICON stage 1 1.00 
  
  1.00 
  
  
  2 0.78 0.14 4.81 0.78 0.91 0.23 4.10 0.897 
  3-4 2.88 0.68 15.18 0.15 1.92 0.52 8.07 0.329 
 
Table A1 Adjusted hazard ratios for ICON for HRHPV+ patients only (N=124) 
 
 
 
 
 
 
 
Figure 1 Survival plots for OS (plot for ICON stage are only for the subset of HRHPV+ patients) 
 
 
 
Figure 2 Survival plots for PFS (plot for ICON stage are only for the subset of HRHPV+ patients) 
 
 
  
 
 
 
 
